{"entity":{"id":"nct07211958","kind":"trial","name":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","aka":["REVEAL-ND NPM1"],"tldr":"A phase 3 trial of Revumenib in acute myeloid leukaemia, run by Syndax Pharmaceuticals, now recruiting.","summary":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation is a phase 3 interventional study registered as NCT07211958 by Syndax Pharmaceuticals, with 468 participants planned, started 2025-11-25 and due to reach its primary completion in 2029-06. Interventions recorded: Revumenib, Placebo and Intensive Chemotherapy Regimen.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07211958","url":"https://clinicaltrials.gov/study/NCT07211958"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":["epigenetic-drugs"],"targets":[],"drugs":["revumenib"],"companies":["syndax"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07211958","phase":"3","setting":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation","sponsor":"Syndax Pharmaceuticals","participation":[{"nct":"NCT07211958","source":"https://clinicaltrials.gov/study/NCT07211958","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"05ecdfb9d46a29945cb15185806c7411240876925ec1811bfc4d8e1dfc5e3c44","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Syndax Pharmaceuticals","collaboratorCount":0,"minimumAge":"12 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":468,"enrolmentType":"ESTIMATED","siteCount":149,"recruitingSiteCount":149,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","France","Georgia","Germany","Greece","Hungary","Israel","Italy","Lithuania","Malaysia","Poland","Romania","Singapore","South Korea","Spain","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-11-25","startedType":"actual","enrolled":468,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07211958/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"}],"drug":[{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/"}],"company":[{"id":"syndax","kind":"company","name":"Syndax Pharmaceuticals","route":"/companies/syndax/"}]}}